Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

Launched by MAYO CLINIC · Aug 30, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at three different treatment options for patients with pelvic bone sarcomas, which are cancers that affect the bones in the pelvic area. The treatments being compared are carbon ion therapy, surgery (with or without proton therapy), and proton therapy alone. The main goal of the study is to see which treatment helps control the cancer better and has fewer side effects, while also improving the quality of life for patients.

To be eligible for this trial, participants should be at least 15 years old and have a confirmed diagnosis of specific types of pelvic bone sarcomas. They should not have any signs of the cancer spreading to other parts of the body and must be able to understand and complete questionnaires about their health. If someone joins the trial, they will receive one of the treatment options and will be monitored for their health outcomes and how they feel during and after treatment. It's important to note that the trial is currently recruiting new participants, and those who are pregnant, nursing, or have had certain previous treatments may not qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females \>= 15 years of age
• • Newly diagnosed, histologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement or non-RMS soft tissue sarcoma with bone involvement
• • No evidence of distant sarcoma metastases as determined by clinical examination and any form of imaging
• • Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2
• • Patients capable of childbearing must agree to use adequate contraception
• • Ability to complete questionnaire(s) by themselves or with assistance
• • Ability to provide written informed consent
• • Chemotherapy per institutional guidelines is allowed
• Exclusion Criteria:
• • Patients receiving palliative treatment
• • Recurrent disease
• • Males and females \< 15 years of age
• • Previous radiation therapy to the site of the sarcoma or area surrounding it such that it would be partially or completely encompassed by the radiation volume needed to treat the current sarcoma. In other words, treatment on this study would require re-irradiation of tissues
• • Patients with distant sarcoma metastases
• • Benign pelvic bone histologies
• * Any of the following:
• • Pregnant women
• • Nursing women
• • Men or women of childbearing potential who are unwilling to employ adequate contraception